Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Barclay CTA Index gains 0.24% in June (-1.04% YTD); currency and agricultural traders lead the pack

Monday, July 19, 2010
Opalesque Industry Updates - Managed futures gained 0.24% in June according to the Barclay CTA Index compiled by BarclayHedge. The Index is down 1.04% for the first six months of 2010.

“Risk aversion driven by concerns of a ‘double-dip’ recession helped push global bond prices higher again in June, providing profitable trading opportunities for managers favoring the long side of the interest rate markets,” says Sol Waksman, founder and president of BarclayHedge.

Four of Barclay’s six managed futures sectors had gains in June. The Barclay Financial & Metals Traders Index was up 0.28%, Discretionary Traders gained 0.14%, Agricultural Traders were up 0.10%, and Diversified Traders rose 0.09%.

Currency traders had a difficult month, as the Barclay Currency Traders Index lost 0.51% in June.

“Although the Euro continued its downtrend against the US Dollar, solid rallies in Yen, Sterling and Swiss Franc exchange rates versus the Dollar created tricky cross-currents for traders to navigate,” says Waksman.

The largest managed futures traders lost ground in June, falling 0.36% as measured by the Barclay BTOP50 Index. The BTOP50 is down 1.27% after six months.

Currency Traders are up 2.13% after the first two quarters of 2010, and Agricultural Traders have gained 2.11%.

Diversified Traders have lost 2.90% year-to-date, and Systematic Traders are down 1.53%.

“During the first half of 2010, diversification across the various market sectors has not been beneficial for CTAs,” says Waksman. “The best performance has been in currencies and the agricultural sector.”

Source

kb

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for